tetano
Editor, Senior Moderator
Sci Rep. 2020 Feb 20;10(1):3044. doi: 10.1038/s41598-020-59732-7. [h=1]Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis.[/h]
Zhou Y[SUP]1[/SUP], Fu X[SUP]1[/SUP], Liu X[SUP]1[/SUP], Huang C[SUP]1[/SUP], Tian G[SUP]1,[/SUP][SUP]2[/SUP], Ding C[SUP]1[/SUP], Wu J[SUP]1[/SUP], Lan L[SUP]1[/SUP], Yang S[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza-related severe pneumonia and acute respiratory distress syndrome (ARDS) are severe threats to human health. The objective of this study was to assess the effects of systematic corticosteroid therapy in patients with pneumonia or ARDS. The PubMed, EMBASE, Web of Science and SCOPUS databases were searched up to July, 2019. Nineteen studies including 6637 individuals were identified, and fifteen studies (6427 patients) were included in the meta-analysis of mortality. Eighteen were observational studies and one was a randomized controlled trial (RCT). The meta-analysis results showed that corticosteroid therapy was associated with significantly higher mortality (OR 1.53, 95% CI [1.16, 2.01]) and incidence of nosocomial infection (OR 3.15, 95% CI [1.54, 6.45]). Subgroup analysis showed that among patients with unadjusted estimates, the odds of mortality were higher in patients receiving corticosteroid treatment (OR 1.98, 95% CI [1.23, 3.17]), however, among patients with adjusted estimates, the result showed no statistically significant difference between corticosteroid group and control group (OR 1.31, 95% CI [0.95, 1.80]). Current data do not support the routine use of corticosteroids in patients with influenza severe pneumonia or ARDS. RCTs are needed to provide more robust evidence.
PMID: 32080223 DOI: 10.1038/s41598-020-59732-7
Free full text
Zhou Y[SUP]1[/SUP], Fu X[SUP]1[/SUP], Liu X[SUP]1[/SUP], Huang C[SUP]1[/SUP], Tian G[SUP]1,[/SUP][SUP]2[/SUP], Ding C[SUP]1[/SUP], Wu J[SUP]1[/SUP], Lan L[SUP]1[/SUP], Yang S[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza-related severe pneumonia and acute respiratory distress syndrome (ARDS) are severe threats to human health. The objective of this study was to assess the effects of systematic corticosteroid therapy in patients with pneumonia or ARDS. The PubMed, EMBASE, Web of Science and SCOPUS databases were searched up to July, 2019. Nineteen studies including 6637 individuals were identified, and fifteen studies (6427 patients) were included in the meta-analysis of mortality. Eighteen were observational studies and one was a randomized controlled trial (RCT). The meta-analysis results showed that corticosteroid therapy was associated with significantly higher mortality (OR 1.53, 95% CI [1.16, 2.01]) and incidence of nosocomial infection (OR 3.15, 95% CI [1.54, 6.45]). Subgroup analysis showed that among patients with unadjusted estimates, the odds of mortality were higher in patients receiving corticosteroid treatment (OR 1.98, 95% CI [1.23, 3.17]), however, among patients with adjusted estimates, the result showed no statistically significant difference between corticosteroid group and control group (OR 1.31, 95% CI [0.95, 1.80]). Current data do not support the routine use of corticosteroids in patients with influenza severe pneumonia or ARDS. RCTs are needed to provide more robust evidence.
PMID: 32080223 DOI: 10.1038/s41598-020-59732-7
Free full text